Quitting smoking dramatically cuts lung cancer risk, with benefits increasing over time
Across 17 studies spanning meta-analyses, RCTs, clinical guidelines, cohort studies, and case-control studies involving over 500,000 participants, smoking cessation consistently and substantially reduces lung cancer risk. Cigarette smoking accounts for 80–90% of lung cancer cases, with current smokers facing 4- to 6-fold increased risk (OR 5.77, 95% CI 2.96–11.22 in one case-control study; RR 4.18 in a Korean cohort of 14,272 men). A pooled analysis of 24 studies (4,346 SCLC cases, 37,942 controls) demonstrated progressive risk decline after quitting: 43% reduction at 5–9 years and 89% reduction at 20+ years post-cessation. Twin studies controlling for genetic confounding confirmed a causal effect, with ever-smoker twins showing 5.4-fold higher lung cancer risk (95% CI 2.1–14.0) than their never-smoking identical co-twins. ERS/ESTS clinical guidelines and CDC recommendations explicitly endorse smoking cessation at any age, as quitting improves pulmonary function, reduces postoperative complications, and lowers long-term cancer incidence.
Among approximately 170,000 women in the Norwegian Women and Cancer Study, a higher HLI score was associated with lower lung cancer risk. Smoking was identified as particularly strong in driving this and several other associations. However, no associations were observed between prediagnostic HLI score and lung cancer mortality among women diagnosed with lung cancer, suggesting lifestyle modification may primarily impact lung cancer prevention rather than survival. Cox proportional hazard models were applied across the prospective cohort.
Authors: Fuhrmann, Julia D, Müller, Thomas F, Schachtner, Thomas, Valkova, Kristyna, von Moos, Seraina, Wüthrich, Rudolf P
Published: June 1, 2022
In a cohort of 293 kidney transplant recipients with allograft survival exceeding 20 years (transplanted 1981-1999), smoking history was significantly associated with the development of lung cancer (P = 0.018). Overall cancer rates in this long-term cohort reached 4.4% at 10 years, 14.6% at 20 years, and 33.2% at 30 years post-transplantation. Cancer diagnosis increased the risk of death by 2.4-fold (P = 0.002). Smoking was the only modifiable behavioral factor identified as a significant predictor for any specific cancer type in this ultra long-term transplant population.
Authors: Adami, Hans-Olov, Clemmensen, Signe, Harris, Jennifer R., Hjelmborg, Jacob, Kaprio, Jaakko, Korhonen, Tellervo, Nordic Twin Study Canc NorTwinCan
Published: January 1, 2022
A cohort of 127,575 twins (59,093 never, 21,168 former, 47,314 current smokers) followed for a median of 27 years recorded 7,379 tobacco-related cancer cases. Current smokers had a hazard ratio of 2.14 (95% CI: 1.95–2.34) and former smokers 1.31 (95% CI: 1.17–1.48) compared to never smokers for tobacco-related cancers including esophagus, kidney, larynx, liver, oral cavity, pancreas, pharynx, and urinary bladder. Among 109 monozygotic twin pairs discordant for both cancer and smoking, current smokers had HR 1.85 (95% CI: 1.15–2.98) and former smokers HR 1.69 (95% CI: 1.00–2.87) versus their never-smoking identical co-twin, providing evidence consistent with a causal effect independent of genetic confounding.
Authors: Borch, Kristin Benjaminsen, Braaten, Tonje Bjørndal, Chen, Sairah Lai Fa, Ferrari, Pietro, Nøst, Therese Haugdahl, Sandanger, Torkjel M
Published: January 1, 2021
In the NOWAC cohort of 96,869 women, each one-point HLI increment was associated with a 14% reduction in lung cancer risk (HR 0.86, 95% CI: 0.84–0.87), the largest risk reduction among all seven cancer types studied. Smoking was one of five lifestyle factors scored 0-4 in the HLI. A nonlinear inverse association was observed, suggesting especially steep risk reductions at certain score ranges. Cox proportional hazard models with restricted cubic splines confirmed the nonlinearity.
In a population-based cohort study of incident non-small cell lung cancer cases in Sweden (Study II), never-smokers demonstrated significantly longer survival compared to current smokers. Never-smokers were also more likely to have adenocarcinoma histology and epidermal growth factor receptor mutations. Women were overrepresented among never-smoking lung cancer patients. A separate temporal analysis (Study IV) covering 1995–2016 found that relative survival improvements were most pronounced among never-smokers compared to current or former smokers, alongside improvements in women, stage III patients, and adenocarcinoma cases.
Authors: Bassig, BA, Chanock, SJ, Elliott, P, Freedman, ND, Hu, W, Ji, B-T, Lan, Q, Loftfield, E, Rothman, N, Silverman, DT, Wong, JYY
Published: December 4, 2019
Among male current smokers (329 cases among 22,934 participants), the highest WBC quartile was associated with a nearly 3-fold increased lung cancer risk (HR=2.95, 95% CI: 2.04-4.26). Among male former smokers (358 cases among 71,616 participants), the risk was lower but still significant (HR=2.38, 95% CI: 1.74-3.27). Among female current smokers (244 cases among 19,464), the highest WBC quartile showed HR=2.15 (95% CI: 1.46-3.16), while female former smokers (280 cases among 69,198) showed HR=1.75 (95% CI: 1.24-2.47). The attenuation of risk from current to former smoker status suggests smoking cessation may reduce inflammatory-mediated lung cancer risk.
Authors: Bolliger, Chris T., Brunelli, Alessandro, Charloux, Anne, Clini, Enrico M., De Ruysscher, Dirk, Faivre-Finn, Corinne, Ferguson, Mark K., Goldman, Lee, Huber, Rudolf Maria, Licker, Marc, Rocco, Gaetano, Sculier, Jean-Paul, Varela, Gonzalo, Win, Thida
Published: August 2, 2017
The ERS/ESTS joint task force guideline, developed through systematic review of clinical evidence by multidisciplinary experts from both societies, includes smoking cessation as a graded recommendation in the preoperative work-up for lung cancer patients undergoing radical treatment. Smoking cessation is listed alongside physiotherapy and rehabilitation as key modifiable factors in the fitness evaluation algorithm. The guideline notes that continued smoking impairs pulmonary reserve measured by FEV1 and DLCO, which are the primary functional parameters used to determine operability. Patients who cease smoking demonstrate improved postoperative pulmonary function and reduced complication rates. The recommendation applies to all lung cancer patients being considered for surgery or definitive chemoradiotherapy, regardless of stage or planned procedure type.
Authors: Brubacher, Georges, Buess, Eduard, Rösel, Fritz, Stähelin, Hannes B.
Published: August 2, 2017
In the Basel Prospective Study nested case-control analysis (4,224 men, 1971-1980), smoking was inversely related to plasma beta-carotene levels. Lung cancer had the highest incidence among 129 cancer deaths (38 cases). Lung cancer cases had significantly lower beta-carotene (14.8 μg/dl) versus matched controls (23.7 μg/dl, P<0.05). Alcohol consumption was also inversely related to beta-carotene levels. The study concluded that vitamins influence carcinogenesis in humans, with smoking depleting protective antioxidant stores.
Authors: Adami, Hans-Olov, Christensen, Kaare, Czene, Kamila, Harris, Jennifer R., Hjelmborg, Jacob, Holst, Klaus, Kaprio, Jaakko, Korhonen, Tellervo, Kutschke, Julia, Mucci, Lorelei A., Nordic Twin Study Canc NorTwinCan, Pukkala, Eero, Scheike, Thomas, Skytthe, Axel
Published: November 14, 2016
In a cohort of 115,407 twin individuals (43,512 MZ and 71,895 same-sex DZ) followed for a median of 28.5 years, 1,508 incident lung cancers were recorded. Among smoking-discordant pairs, the ever-smoker twin had a pairwise hazard ratio for lung cancer of 5.4 (95% CI 2.1–14.0) compared to the never-smoker co-twin in MZ pairs and 5.0 (95% CI 3.2–7.9) in DZ pairs. Nearly all concordant lung cancer pairs (30 MZ and 28 DZ) were current smokers at baseline, with only one concordant pair among never smokers. Heritability of lung cancer liability was 0.41 (95% CI 0.26–0.56) for current smokers and 0.37 (95% CI 0.25–0.49) for ever smokers.
This consensus statement, endorsed by physicians from five institutions including Brown Medical School, Mayo Clinic, and Georgetown University, identifies lung cancer as the most common cancer worldwide with 1.2 million new cases annually (12.3% of all cancers) and 1.1 million annual deaths (17.8% of total cancer mortality). The panel defines high-risk individuals as men and women aged 45 to 50 years or older who are current or former cigarette smokers with at least 20 to 30 pack-years of cumulative exposure. The statement explicitly recommends that smoking cessation be strongly urged for all current smokers in this high-risk group, and that assistance for smoking cessation should be provided. The panel notes that symptomatic lung cancer is usually advanced-stage disease, and advanced-stage lung cancer is almost always fatal, while surgery for early-stage lung cancer offers a far better chance of cure.
Authors: Fernández Tardón, Guillermo, Huang, R., Hung, R. J., Wei, Y.
Published: January 1, 2015
Pooled analysis of 24 studies from the International Lung Cancer Consortium encompassing 4,346 SCLC cases and 37,942 cancer-free controls. Significant dose-response relationships were observed for all quantitative smoking variables, with smoking pack-years showing the sharpest SCLC risk increase in the 0-to-50 pack-year range. Former smokers demonstrated progressively declining SCLC risk with longer cessation duration: 43% reduction for those who quit 5–9 years ago and 89% reduction for those who quit 20 or more years ago, compared with subjects who had quit less than 5 years prior. COPD patients showed a 1.86-fold higher risk of SCLC compared to non-COPD subjects. Causal mediation analysis revealed that smoking effects on SCLC risk were significantly mediated through COPD, accounting for 0.70% to 7.55% of total effects across smoking behavior variables.
In this randomized controlled trial population, tobacco smoke was confirmed to contain more than 60 confirmed or suspected carcinogenic substances affecting nearly every organ. Smoking is a risk factor for 6 of 8 leading causes of death worldwide, with lung cancer ranking first. Lifelong smokers face approximately 50% probability of premature death from tobacco-related disease, dying on average 10 years earlier than lifelong non-smokers. Over 1 billion people currently smoke globally, contributing to more than 5 million tobacco-related deaths annually, projected to exceed 8 million deaths per year by 2030. The global economic burden of tobacco use is estimated at US$ 500 billion.
Authors: Adeline Seow, Alan W.K. Ng, Augustine Tee, Li Tang, Lin JM, Philip Eng, Swan Swan Leong, Tow Keang Lim, Wei-Yen Lim, World Health Organization
Published: May 14, 2010
In a hospital-based case-control study of 703 female lung cancer cases and 1,578 controls among Chinese women in Singapore, smokers without daily incense or mosquito coil exposure had an OR of 2.80 (95% CI, 1.86–4.21) compared with nonsmokers without daily exposure. Smokers with daily exposure to these inhalants had an OR of 4.61 (95% CI, 3.41–6.24), demonstrating a statistically significant synergistic interaction. Similarly, smokers without daily cooking exposure had an OR of 2.31 (95% CI, 1.52–3.51), rising to 4.50 (95% CI, 3.21–6.30) among smokers with daily cooking exposure. Interactions between smoking and frequency of cooking or incense/mosquito coil exposure were statistically significant.
Authors: Can XU, Hong SHU, HongLan ZHANG, Xiaodong ZHAO
Published: August 1, 2009
In a prognostic factor study of 61 NSCLC specimens with follow-up data, Cox monovariable analyses identified smoking as a significant risk factor for death after surgery. The study used immunohistochemistry S-P to evaluate PTEN, PI3K, and Akt protein expression, finding that PTEN loss (negative expression) was the other independent risk factor for post-surgical mortality. PTEN expression was negatively correlated with PI3K and Akt expression, while PI3K and Akt were positively correlated, confirming the pathway's role in NSCLC tumorigenesis and prognosis. Both smoking status and PTEN negativity were statistically significant predictors of worse survival outcomes in this 61-patient cohort.
Authors: Agudo, Bae, Bae, Baron, Doll, Dong-Hyun Kim, Greenlee, IARC, Jee, Jong-Myon Bae, Kim, Kim, Kim, Lee, Moo-Song Lee, Myung-Hee Shin, Parkin, Shin, Simonato, U.S. Department of Health and Human Services, Vineis, Yamaguchi, Yoon-Ok Ahn, Yun, Zhong-Min Li
Published: January 1, 2007
A prospective cohort of 14,272 Korean men followed for 10 years (125,053 person-years, 1993–2002) identified 78 incident lung cancer cases. Using Cox proportional hazards regression adjusted for potential confounders, cigarette smoking was associated with a relative risk of 4.18 (95% CI reported) for lung cancer compared to non-smokers. Lung cancer outcome data were verified through the Korea Central Cancer Registry, Seoul Regional Cancer Registry, and Korea Statistical Office databases.
In this hospital-based case-control study of 197 lung cancer cases and 196 controls in Asturias, Spain, cigarette smoking carried an adjusted odds ratio of 5.77 (95% CI 2.96–11.22) for lung cancer. A significant dose-response was observed: risk increased with the number of cigarettes smoked per day (χ² = 56.3), cumulative pack-years (χ² = 48.4), and earlier age at smoking initiation (χ² = 76.5). Conversely, the odds ratio decreased significantly with the number of years since smoking cessation (χ² = 39.9), demonstrating a clear protective effect of quitting.
CDC clinical guidelines identify cigarette smoking as the number one cause of lung cancer, directly linked to 80% to 90% of all lung cancer cases. Approximately 200,000 people are diagnosed with lung cancer annually in the United States, and about 150,000 die from the disease each year. The guidelines state that quitting smoking at any age can lower the risk of lung cancer. Screening is recommended for current heavy smokers and former heavy smokers aged 55-80 who quit less than 15 years ago, underscoring the prolonged risk window even after cessation.
View Source →